Life Science Access Academy Ltd invites you to their event
About this event
Join us as we navigate through the rhetoric and unravel the profound realities that surround the cutting-edge field of science which is gene therapy.
In this timely 60-minute masterclass for LSAA members our esteemed panel will cut through the hype and get to the heart of the matter. Addressing misconceptions and demystifying complexities, Gene Therapy: Rhetoric versus Reality promises an illuminating experience that will leave you informed, inspired, and ready to contribute.
We will also reflect on the exciting views of Professor Eric Alton, expert in gene and cell therapy.
Hosted by
In 2022, after gaining five years of valuable experience in the gene therapy sector with a focus on reimbursement and commercialization at Bluebird Bio in Europe, Nicola established NJ Redfern Ltd. Her expertise in rare diseases, oncology, and hematology has been dedicated to pricing, reimbursement, service delivery, and shaping the external landscape.
Owen draws on his experience as a leader, driven to address inequality and unfairness through his work in rare diseases, bringing breakthrough treatments to patients, and leading work to improve diversity, inclusion, and belonging for people at work.
Direction of Commissioning and Contracting in Shropshire for 4 years before moving to current role in a newly formed ICB, leading a Place, with system level responsibility for delegation of specialised services, LTC, Elective and Diagnostics and Mental Health.
Henry is the founder of Oxygen - a strategic healthcare public affairs company based in the new diplomatic precinct of Nine Elms in London.
Ian co-founded the Life Science Access Academy with Nigel Robbins to bring together all the best ideas in people development from more than 20 innovative specialist consultancies.
LSAA is a truly Global Membership Community for all staff from across the Life Science sector including: commercial, clinical and financial sales teams, medics and support teams.
